Sanofi-Aventis, Frankfurt, Germany.
Handb Exp Pharmacol. 2024;286:1-19. doi: 10.1007/164_2024_724.
Initiatives to share assets in the life science sector through dedicated partnerships had and still have a multitude of different aspects in the past few decades. The range goes from industry partners, small and big companies, in bilateral agreements with academic institutions up to large privately and publicly funded consortia. In general, the term public-private partnership (PPP) is used when at least one public (non-profit, academic, and/or government) part and one or more private for-profit partners are involved. A Public-Private Partnership is often driven by a public body, i.e. a ministry or a public agency. Their synergism has been described 10 years ago (Dearing, Science 315(19):344-347, 2007; Casty and Wieman, Ther Innov Regul Sci 47(3):375-383, 2013; Stevens et al., Biotechnol Law Rep 34(4):153-165, 2015). So why view this synergism again today? It will be shown that the situation in life science has changed: novel partners acting digital, data expertise being involved on many levels and novel partnering models arising. Success and challenges will be described in this chapter.
过去几十年,通过专门的合作伙伴关系共享生命科学领域资产的举措层出不穷,具有多种多样的不同方面。合作范围涵盖了双边协议中的行业合作伙伴、大小公司,以及大型私人和公共资助的财团。通常,当至少有一个公共(非营利、学术和/或政府)部门和一个或多个私人盈利伙伴参与时,就会使用公私合作伙伴关系(PPP)这一术语。公私合作伙伴关系通常由公共机构(如部委或公共机构)推动。它们的协同作用在 10 年前就已经被描述过(Dearing,Science 315(19):344-347, 2007;Casty 和 Wieman,Ther Innov Regul Sci 47(3):375-383, 2013;Stevens 等人,Biotechnol Law Rep 34(4):153-165, 2015)。那么,为什么今天还要再次审视这种协同作用呢?事实将表明,生命科学领域的情况已经发生了变化:新的数字行动者合作伙伴、涉及多个层面的数据专业知识以及新的合作模式正在出现。本章将描述成功和挑战。